New treatment strategy may thwart deadly brain tumours
New research in mice led by investigators at Massachusetts General
Hospital (MGH) and the University of Florida reveals a promising
strategy that makes glioblastoma susceptible to these medications. The
findings, which are published in the Proceedings of the National Academy of Sciences, indicate that such combination therapy should be tested in clinical trials of patients with glioblastoma, for whom there is no known cure.
Part of the reason glioblastoma do not respond well to immune checkpoint inhibitors and other immunotherapies is because cells called myeloid-derived suppressor cells (MDSCs) infiltrate the region surrounding glioblastoma tumours, where they contribute to immunosuppression, tumour progression, and treatment resistance. Thus, targeting these cells may augment immunotherapy and improve responses to treatment in affected patients.
A collaborative effort co-led by Jeffrey K. Harrison, PhD, of the Department of Pharmacology and Therapeutics at the University of Florida, and Rakesh K. Jain, PhD, of the Department of Radiation Oncology at MGH and Harvard Medical School, set out to test this strategy.
Using two mouse models of glioblastoma, the team targeted receptors–called chemokine receptors–that are important for allowing MDSCs to infiltrate into the region surrounding glioblastoma tumours. In mice that were bred to lack chemokine receptor 2 (CCR2) and to develop glioblastoma, MDSCs could not carry out such infiltration.
Treating these mice with an immune checkpoint inhibitor stimulated a strong anti-cancer immune response and prolonged the animals’ survival. In mice with normal CCR2, treatment with a molecule that blocks CCR2 had similar effects.
According to Jain, “The CCR2 antagonist used in this study–called CCX872– has passed phase Ib safety trials in patients with pancreatic tumours, and clinical trials are ongoing to investigate the use of CCR2 inhibitors in several cancers.”
“Thus, the results of this study support targeting CCR2-expressing MDSCs as a means to enhance immunotherapies, and warrant investigation of this combination therapy in clinical trials for patients with glioblastoma,” says Jain.
Part of the reason glioblastoma do not respond well to immune checkpoint inhibitors and other immunotherapies is because cells called myeloid-derived suppressor cells (MDSCs) infiltrate the region surrounding glioblastoma tumours, where they contribute to immunosuppression, tumour progression, and treatment resistance. Thus, targeting these cells may augment immunotherapy and improve responses to treatment in affected patients.
A collaborative effort co-led by Jeffrey K. Harrison, PhD, of the Department of Pharmacology and Therapeutics at the University of Florida, and Rakesh K. Jain, PhD, of the Department of Radiation Oncology at MGH and Harvard Medical School, set out to test this strategy.
Using two mouse models of glioblastoma, the team targeted receptors–called chemokine receptors–that are important for allowing MDSCs to infiltrate into the region surrounding glioblastoma tumours. In mice that were bred to lack chemokine receptor 2 (CCR2) and to develop glioblastoma, MDSCs could not carry out such infiltration.
Treating these mice with an immune checkpoint inhibitor stimulated a strong anti-cancer immune response and prolonged the animals’ survival. In mice with normal CCR2, treatment with a molecule that blocks CCR2 had similar effects.
According to Jain, “The CCR2 antagonist used in this study–called CCX872– has passed phase Ib safety trials in patients with pancreatic tumours, and clinical trials are ongoing to investigate the use of CCR2 inhibitors in several cancers.”
“Thus, the results of this study support targeting CCR2-expressing MDSCs as a means to enhance immunotherapies, and warrant investigation of this combination therapy in clinical trials for patients with glioblastoma,” says Jain.